[go: up one dir, main page]

0% found this document useful (0 votes)
85 views58 pages

Atherosclerosis

Download as pdf or txt
Download as pdf or txt
Download as pdf or txt
You are on page 1/ 58

BBMS3014

ATHEROSCLEROSIS

Connie Woo PhD RPh


Department of Pharmacology and Pharmacy
cwhwoo@hku.hk
WHAT IS ATHEROSCLEROSIS?

athero-, ather- +
(Greek: groats, meal, porridge; soft, pasty materials)

sclero-, scler-
(Greek: hard, hardening)

What is your understanding based on this word origin/root?

What is the difference between arteriosclerosis vs. atherosclerosis?


Heart Attack
WHY DO WE CARE? Heart Failure
(coronary artery)
What is the problem of atherosclerosis? Stroke
Causes of death in men and women aged 15-69 years
(carotid artery)

Peripheral
Artery Disease
Aneurysm

http://www.who.int/nmh/publications/ncd_report_chapter1.pdf?ua=1
WHO IS AT RISK?
High cholesterol
What are the risk factors? Diabetes
Obesity
High CRP
Smoking

Circulation. 2004;109[suppl III]:III-15–III-19.)


HOW CAN IT BE DIAGNOSED?
 Blood tests
 Ankle/brachial index

 Electrocardiogram (ECG, EKG)

 Stress test

 Echocardiogram

 Nuclear Heart Scan

 Computed tomography (CT) scan

 Angiography

Physical Exam first >>> high risk  specific tests


Framingham Risk Score
Blood tests

 Screening risk factors


 Fasting blood glucose

 Lipid profile
 Triglyceride
 Cholesterol
 HDL
 LDL

 C-reactive protein (CRP)


 Homocysteine (Hcy), not
routinely done because of
the cost
Ankle/Brachial index
 To predict peripheral arterial disease
Electrocardiogram (ECG or EKG)
 A test that records your heart’s electrical activity
 Reveal abnormal heartbeats or heart damages

 Atrial fibrillation, left ventricle hypertrophy, etc.


Stress test
 Sometimes it is easier to diagnose
problems if heart is working hard /
beating fast.
 A patient exercises on a treadmill
or a stationary bicycle (sometimes
drug is given to make your heart
beat faster)
 An EKG (or nuclear scanning) is
done before, during and after the
stress test.
 Breathing, blood pressure are also
monitored.
Echocardiogram (Ultrasound)
 Examines heart using sound waves,
creating a moving picture of the
organ.
 Can be done while a person is at
rest or exercising (“stress
echocardiogram”).
 Provides information:
 Size and shape of your heart
 Functional ability of your heart
chambers and valves.
 Identify heart muscle that are not
contracting normally.
 Identify area of poor blood flow.
Computed Tomography (CT) Scan
 Series of X-rays in “slices” through the body
 Analyzed by a computer
 3-D image constructed
 A contrast dye (e.g. iodine) will be injected prior to the scan.
 Abnormal tissues have different absorption rate.
 Identify and measure calcium buildup in and around the coronary
arteries, before you have any CVD symptoms.
 Precise location
 Solid
 Shape

Contrast is needed
Sit in scanner (15-20 mins)
Cannot detect small size (<2cm in size)
Angiography
 Thin flexible tube is passed through
an artery, at the top of the leg or in
the arm to reach the arteries.
 Look inside your artery to see if there
is any blockage.
 A dye can be injected into the arteries
and monitor by x-ray to observe blood
flow.
 Carried out during cardiac
catheterization (coronary
angiography).
 Limitations:
 Invasive
 Provides dimensions of lumen only
 Radiation exposure
Magnetic resonance imaging (MRI)
 Uses a magnetic field from super
cooled magnets (NOT X-RAYS).
 The strength of the magnetic field
cause the atoms of the body to
response, and the emissions are
detected by the scanner >
Analyzed> Image produced.
 Shows detailed images of the
structure and beating of the
heart.
 Image are detailed and very clear
(better than a CT scan).
 Can distinguish between disease
and healthy tissues. Difficult to
differentiate inflamed and scar
tissues.
 Not suitable for people who have
metal implants.
HOW DOES ATHEROSCLEROTIC LESION DEVELOP?

Koenig W. et al. ATVB. 2007;27:15-26

Stary H C et al. Circulation. 1995;92:1355-1374


Human coronary lesion consistent with pathologic intimal thickening (A to D).

Kolodgie F D et al. Arterioscler Thromb Vasc Biol. 2007;27:986-989


Historical Breakthrough (1)

J Clin Invest. 1973 Jul;52(7):1533-43.


Historical Breakthrough (2)

2004
Historical Breakthrough (3) ?

Clinical evidence?

Nature Reviews Immunology 10, 36-46, 2010


Development of Atherosclerosis
(Cellular level)

Nature. 2011 May 19;473(7347):317-25.


Development of Atherosclerosis
(Molecular level)

Nature. 2011 May 19;473(7347):317-25.


Regression of Atherosclerosis ?

Figure 2 Retention, responses, and regression

Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal.
Williams, Kevin; Feig, Jonathan; Fisher, Edward. Current Opinion in Lipidology. 18(4):443-450, August 2007.
Regression of Atherosclerosis
(Reverse Cholesterol transport in macrophage)

Cuchel M , and Rader D J Circulation. 2006;113:2548-2555

HDL metabolism and macrophage RCT. The liver and intestine synthesize and secrete apoA-I and
are primarily responsible for the lipidation of newly secreted lipid-poor apoA-I via ABCA1-mediated
cholesterol efflux.

Copyright © American Heart Association, Inc. All rights reserved


WHAT ARE THERAPEUTIC STRATEGIES?

• Cholesterol mechanism ↑HDL and ↓LDL

• Anti-inflammatory NSAID, Aspirin

• Anti-apoptotic Chemical Chaperone

From these three perspectives, what are our options?


Cholesterol management
Low Risk
•0-1 risk factors.
•10 year CVD event rate <10%
•Cholesterol target <160mg/dl.
Risk Factors:
Moderate Risk
•Multiple (>2) risk factors • Old age
•10 year CVD event risk <10%. • Obesity
•Cholesterol target <130mg/dl. • High cholesterol
Moderate to High Risk • High blood pressure
•Multiple (>2) risk factors • Smoking
•10 year CVD event risk of 10-20%. • Diabetes
•Cholesterol target <100mg/dl • Insulin resistant
• CRP
Moderate to High Risk • Lack of physical
Multiple risk activity…
•Established CVD (i.e. prior MI, ischemia, angina
pectoris, coronary angioplasty/stent, periphery
artery disease, aneurysm, carotid artery disease)
•10 year CVD event risk >20%
•Cholesterol target <70mg/dl
“Anti” cholesterol
Cholesterol: 50% made by our body and 50% absorbed
through diet
• Decrease absorption
• Increase excretion
• Decrease synthesis

Statins: HMG-CoA reductase inhibitor


Cholestyramine: bile acid sequestrant
Fibrate
Niacin
CETP inhibitor: Evacetrapib
Hypercholesterolemia
1. Statin
HMG-CoA Reductase inhibitors
 Lovastatin (Mevacor)
 Pravastatin (Pravachol)
 Simvastatin (Zocor)
 Rosuvastatin (Crestor)
 Atorvastatin (Lipitor)
 Fluvastatin (Lescol)
 Pitavastatin (Livalo)
Hypercholesterolemia
2. Bile Acid Sequentrants

J Lipid Res 42: 1594-1603, 2001

Cholestyramine (Prevalite)
Colesevelam (Welchol)
Colestipol (Colestid)
Hypercholesterolemia
3. Cholesterol absorption inhibitors

Binding on Niemann-Pick C1-Like 1


protein (NPC1L1)
Ezetimibe (Zetia)
In combination
 Liptruzet® (containing Atorvastatin, Ezetimibe)
 Vytorin® (containing Ezetimibe, Simvastatin)

Nature Reviews Molecular Cell Biology 9, 125-138, 2008

Nature Clinical Practice Cardiovascular Medicine (2006) 3, 664-672


Hypertriglyceridemia
1. Fibrate

 Fenofibrate (TriCor) ↓ liver's production of VLDL


cholesterol
 Gemfibrozil (Lopid) ↑ removal of triglycerides from blood

Goldenberg I, Benderly M, Goldbourt U - Vasc Health Risk Manag (2008)


Hypertriglyceridemia
2. Niacin (Vitamin B6)
 Unknown mechanism
 may involve several actions, including a decrease in esterification of hepatic
triglycerides.
 decreases the serum levels of apolipoprotein B-100 (apo B)

Song W , and FitzGerald G A J. Lipid Res. 2013;54:2586-2594


Hypertriglyceridemia
3. Omega-3 PUFA
 omega-3-carboxylic acid (Epanova)

Current Opinion in Lipidology. 17(4):387-393, 2006.


Side effects
Statins: Muscle pain and damage, liver damage; fatal: Rhabdomyolysis
Bile Acid Sequentrants: bloating, constipation
Ezetimibe: fever, headache
Fibrate: allergy-like reaction
Niacin: skin flushing, pruritus
Fish oil: Diarrhea, increase LDL
Combination Pills

 Vytorin = Simvastatin + Ezetimibe


 Simcor = Simvastatin + Niacin
To increase HDL
 Approaches to raise HDL - prominent next hurdle in
the management of dyslipidemia
 CVD patients tend to have low levels of HDL

 A depressed HDL cholesterol level is defined as


<40mg/dL, is a powerful predictor of CHD risk

Nicotinic acids (Niacin)


Fibrates – Increase HDL by 10-35%
Statins – Increase HDL by 5-15%
Estrogens – Increase HDL by 10-15%.
Thus far, exercise is the most effective way to increase
HDL
CETP inhibitor – Under trials
Facilitate cholesterol reverse transport

× ×
×
Br J Cardiol 2012;19:126–33
currently under Phase III trial

Obicetrapib
completed Phase II trial
Modulate inflammation

Aspirin
>>anti-inflammation??
>> anti-platelet or anticoagulant 
How about NSAID?

Graham, D.J. et al. Risk of acute myocardial infarction and sudden cardiac
death in patients treated with cyclo-oxygenase 2 selective and non-selective
non-steroidal anti-inflammatory drugs: nested case-control study. Lancet
365, 475-481, 2005.
“…Rofecoxib use increases the risk of serious coronary heart disease compared with celecoxib use. Naproxen use
does not protect against serious coronary heart disease…”

Differential effect of low-dose aspirin for primary prevention of


atherosclerotic events in diabetes management: a subanalysis of the JPAD
trial. Okada, S. et al. Diabetes care 34, 1277-1283, 2011.
“…Low-dose aspirin reduced atherosclerotic events predominantly in the diet-alone group and not in the insulin
or OHA (oral hypoglycemic agents) groups
American Heart Journal 166: 199 – 207, 2013
Anti-apoptosis approaches

Why chemical chaperone?


4-Phenyl butyrate (or Glycerol Butyrate: FDA approved drug for
urea cycle disorder. Nitrogen binding agents.
http://www.sciencemag.org/content/334/6059/1081/F2.large.jpg
Other strategies

Drugs that decrease blood clots


Anticoagulants
Antiplatelet

Drugs that tackle hypertension


Angiotensin-converting enzymes (ACE) inhibitors

Angiotensin II receptor blockers (ARB)


Calcium channel blockers

Drugs that stabilize arrhythmia of


the heart
Beta-blockers
New treatment concept

Circ Res. 2011;109:830-84

Arterioscler Thromb Vasc Biol. 2015. Epud


Atherosclerosis 232 (2014) 242e248

Biomolecule as Drug
What are the concerns?
WHAT CAN WE DO WHEN LESION IS FORMED?

Surgeries
 Coronary angioplasty (“Balloon”)
 Stent placement
 Coronary artery bypass surgery (CABG)
 Carotid artery surgery
 Plaque removal
Coronary angioplasty
 Open blocked or narrowed coronary arteries.
 Relatively non-invasive

 Stent is put into place sometimes

 Usually a planned procedure

 Sometimes performed as an emergency treatment


Stent placement

 Stent is placed over a balloon catheter to prevent


restenosis
 Moved into area of blockage.
 Balloon is inflate.
 Stent expands and locks into place, holding open the
artery.

The stent remains in the artery


permanently.
Newer types of stents are coated with
medication that is slowly released, or in
a spiral form to minimize turbulence.
Coronary angioplasty with stenting - Low
complication rate.
The recovery time is often < 1day
Coronary Bypass surgery
 Uses arteries or veins from other areas
to bypass your disease coronary
arteries.
 Risk of serious complications is higher
than with stenting.
 Recovery time can take weeks, even
months.
 Best for multiple blocks
Carotid artery surgery
 Also called Endarterectomy.
 Remove plaque from the carotid artery in the neck.
 Open the artery and improves blood flow to the brain.
Plaque removal
 Atherorectomy
 A catheter with a rotating shave.
 Plaque cut into tiny particles,
dissipate without causing damage.
 or captured by the catheter and
removed from the body.
 Laser angioplasty (Laser
revascularization)
 A catheter with a laser tip.
 Vaporizes the plaque.
 Don’t work as well as stenting or
bypass surgery.
 They are used less often.
 Usually, it is used to improve the
success of placing a stent
Death Rates for Coronary Heart Disease, Ages 35-74, in Selected Countries,
1990-2010


Therapeutic point of view
Where to go?
Percentage of People with Diabetes Aged 35 Years
or Older Reporting Heart Disease or Stroke, by
Age, United States, 1997–2011

You might also like